 |
Vol.50 No.1 contents | Japanese/English |
 | Full Text of PDF (1061K) Article in Japanese |
- Case Report -
A Case of Lung Mucoepidermoid Carcinoma with EGFR Mutation Successfully Treated by Gefitinib
Takeshi Tamaki1, Tsutomu Tanijiri1, Yuichi Katashiba1, Maiko Imamura1, Seibun Yonezu1, Shirou Fukuhara11Department of Respiratory Medicine, Kansai Medical University Hirakata Hospital, Japan
Background. Pulmonary or bronchial mucoepidermoid carcinoma is a rare subtype of lung cancer, and effective treatment has not yet been established for advanced stage cases. Case. A 41-year-old man with headache and back pain was referred to our hospital because biopsy of a right lower jaw tumor had revealed metastatic carcinoma, and computed tomography revealed a right hilar tumor. In our hospital, fiberoptic bronchoscopy showed stricture of the right middle lobe bronchus and sessile polypoid tumor, and a biopsy specimen revealed high-grade mucoepidermoid carcinoma. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) showed abnormal accumulations in the mediastinal lymph node, and liver, bone, skin and muscular lesions. Multiple metastasis was suspected, and it was classified stage IV (cT1N2M1). After receiving chemotherapy with carboplatin and paclitaxel, the metastatic liver and bone lesions worsened. Gefitinib was administered as a second-line therapy, resulting in a partial response. Molecular screening of the tumor identified an EGFR exon 19 deletion mutation. Conclusion. There is sometimes an EGFR mutation among cases of mucoepidermoid carcinoma. This case suggests that EGFR tyrosine kinase inhibitors could be effective for the treatment of mucoepidermoid carcinoma with EGFR mutation.
key words: Mucoepidermoid carcinoma, EGFR mutation, Gefitinib, High-grade, FDG-PET
Received: June 15, 2009
Accepted: September 14, 2009
JJLC 50 (1): 27-32, 2010
